Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence for the U.S. Preventive Services Task Force

Appendix (Figure 1). CHD = coronary heart disease; CVD = cardiovascular disease; KQ = key question. KQ 1: Does aspirin chemoprevention in patients without known cardiovascular disease reduce the risk for myocardial infarction, stroke, and death? KQ 2: Does aspirin chemoprevention increase major gastrointestinal bleeding, hemorrhagic strokes, or both? KQ 3: What is the balance of benefits and harms for aspirin therapy in patients with different levels of cardiovascular risk?
Appendix (Figure 1). CHD = coronary heart disease; CVD = cardiovascular disease; KQ = key question. KQ 1: Does aspirin chemoprevention in patients without known cardiovascular disease reduce the risk for myocardial infarction, stroke, and death? KQ 2: Does aspirin chemoprevention increase major gastrointestinal bleeding, hemorrhagic strokes, or both? KQ 3: What is the balance of benefits and harms for aspirin therapy in patients with different levels of cardiovascular risk? Analytic framework: aspirin to prevent cardiovascular events.

This Article

  1. Ann Intern Med January 15, 2002 vol. 136 no. 2 161-172
  1. AbstractFREE
  2. Figures
  3. Full Text
  4. Full Text (PDF)

Current Issue

  1. November 17, 2009, 151 (10)
  1. Alert me to current issues